Design Highlights
- The Medicare GLP-1 Bridge program launches on July 1, 2026, providing temporary coverage for specific weight-loss drugs.
- Beneficiaries must be enrolled in a Medicare Part D or MA-PD plan to access GLP-1 drug coverage.
- Eligibility criteria include BMI thresholds and specific health conditions, excluding those with Type 2 Diabetes.
- Beneficiaries pay a flat $50 copay per month for GLP-1 medications, which does not count towards Part D limits.
- Pharmacy staff must follow Bridge-specific rules while adhering to standard Part D guidelines for other medications.
In a world where weight loss is often treated like a secret sauce, the Medicare GLP-1 Bridge is here to shake things up—at least for a limited time. Scheduled to kick off on July 1, 2026, this temporary program from CMS is meant to cover certain GLP-1 weight-loss drugs for eligible Medicare beneficiaries. But hold on! It only runs until December 31, 2027. So, blink, and you might miss it.
The Medicare GLP-1 Bridge launches July 1, 2026, offering temporary coverage for weight-loss drugs—don’t miss out!
This initiative operates across all states and U.S. territories, providing a unique pathway that’s separate from the existing Part D coverage. The catch? You need to be enrolled in a Medicare Part D plan or a Medicare Advantage plan with drug coverage. So, if you haven’t signed up yet, you may want to get on that. Standalone Prescription Drug Plans (PDP) and Medicare Advantage-Prescription Drug (MA-PD) plans are in, but Special Needs Plans (SNPs) and employer group plans (EGWPs) made the cut too. Just remember, you’ve got to be at least 18, and if you’re already using GLP-1s for other conditions, this program isn’t for you.
Eligibility isn’t just about age and enrollment; it’s also about Body Mass Index (BMI). If you have a BMI of 35 or higher and no other conditions, congratulations! You’re in Category 1. If your BMI is between 30 and 34.9 and you have issues like heart failure, you’re in Category 2. And if you’re in that slightly lighter range of 27 to 29.9 but have prediabetes or past heart problems, welcome to Category 3. However, if you have Type 2 Diabetes, sleep apnea, or fatty liver disease, you’re out. Tough luck! Additionally, the GLP-1 drugs can help manage weight and improve health.
As for the cost? Beneficiaries will pay a flat $50 per month for a 28 or 30-day supply. Simple, right? But don’t get too excited; that payment doesn’t count toward your Part D deductible or out-of-pocket limit. Pharmacists won’t be asking how much you make; everyone pays the same fixed rate. Additionally, the program is designed to operate outside the Medicare Part D coverage and payment flow. The total drug cost for GLP-1 injectables is approximately $245 per month, meaning Medicare absorbs the significant remainder beyond the beneficiary’s fixed copay.
Pharmacy operations are streamlined—CMS administers this directly, cutting out the middleman. No separate enrollment is needed for pharmacies to process claims. Just make certain they know the rules, especially since standard Part D coverage decisions still apply for non-Bridge drugs.
